Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Candel Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CADL
Nasdaq
8731
https://www.candeltx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Candel Therapeutics Inc
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
- Apr 12th, 2024 2:00 pm
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
- Apr 11th, 2024 1:00 pm
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
- Apr 9th, 2024 12:00 pm
Retail investors invested in Candel Therapeutics, Inc. (NASDAQ:CADL) up 320% last week, insiders too were rewarded
- Apr 6th, 2024 2:00 pm
Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study
- Apr 5th, 2024 4:10 pm
After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study
- Apr 4th, 2024 4:24 pm
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
- Apr 4th, 2024 12:00 pm
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
- Mar 28th, 2024 8:05 pm
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
- Mar 28th, 2024 12:05 pm
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
- Mar 5th, 2024 9:30 pm
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
- Feb 13th, 2024 12:30 pm
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
- Feb 5th, 2024 1:00 pm
Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409
- Dec 13th, 2023 5:21 pm
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
- Dec 12th, 2023 1:00 pm
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
- Nov 28th, 2023 2:00 pm
Candel Therapeutics Inc (CADL) Reports Q3 2023 Financial Results and Clinical Progress
- Nov 9th, 2023 2:43 pm
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
- Nov 9th, 2023 1:00 pm
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
- Nov 4th, 2023 12:00 pm
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
- Nov 3rd, 2023 4:00 pm
Pleasing Signs As A Number Of Insiders Buy Candel Therapeutics Stock
- Oct 29th, 2023 1:11 pm
Scroll